Exclusive: London’s Pharosyn raises $3M to speed up pharma’s commercial decisions

Pharosyn has picked up a $3 million seed round led by Moonfire Ventures, with Entrepreneurs First, Transpose Platform and General Advance also backing the deal. The London startup hasn’t said what it’s worth. What it has shown, though, is a sharp reduction in the time it takes to turn messy pharma data into something executives can use.

The company says its tools cut report-writing and question-answering from four hours to 15 minutes. That is a brutal kind of efficiency gain in a business where pricing, market access and portfolio decisions can’t sit around waiting for someone to finish stitching together a memo. Pharosyn says senior directors at customers now use its system daily, including at a biopharmaceutical company in the top ten, plus several mid-sized drugmakers.

This is not a drug-discovery play, and that matters. Most of the money in pharma AI has gone toward finding new molecules or speeding up trials. Pharosyn is going after the slower, less glamorous work of commercial and competitive intelligence, the stuff that sits inside business teams and feeds strategy. Its pitch is simple: generic AI is not enough when the output needs to be traceable back to source data.

That insistence on traceability comes straight out of co-founder Stephen Cowley’s Cambridge work on mitigating hallucinations in LLMs. He and Joshua Hampson met at Cambridge, where Cowley studied AI and Hampson biochemistry. The company says that research now underpins its product, which tracks clinical, regulatory and commercial signals, from trial data and deals to hiring trends, epidemiology and social media.

The round follows a pre-seed in 2025 from the same investors, and the new money will go toward hiring engineers and pharma specialists. Pharosyn says its team is currently 11 people. That is still tiny, which is probably the point: if pharma wants faster decisions, it’s going to buy speed from small, sharp teams before it buys another grand theory about “AI transformation.”